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1. Introduction 
Platelets have recently been shown to contain cell 
multiplication stimulating factor(s), acting on cultured 
mouse tibroblasts [ 1 ] monkey arterial smooth muscle 
cells [2] and human fibroblasts and glial cells [3,4]. 
We have used platelet lysate as a stimulating agent to 
study the metabolism of cell associated glycosamino- 
glycans in relation to cell multiplication. Preliminary 
experiments indicate that exposure of human, cultured 
glial cells to a platelet lysate may lead to a release of 
cellular heparan sulphate, in low molecular weight 
form, to the culture medium (unpublished results). 
Since this finding might indicate the presence in 
platelets of a heparan sulphate degrading enzyme, 
the present investigation was undertaken to examine 
the susceptibility of isolated heparan sulphate to 
platelet preparations. The results demonstrate that 
platelets contain a heparan sulphate degrading 
endoglycosidase. The presence of such an enzyme in 
platelets, lacking endogenous heparan sulphate, may 
indicate a previously unknown capacity of platelets 
to modify the heparan sulphate of other cells in the 
vascular space, e.g. endothelial cells. 
2. Materials and methods 
2.1. ChemicaIs 
Carrier-free [35S]sulphate was obtained from the 
Radiochemical Centre, Amersham, UK. Sephadex gels 
were purchased from Pharmacia Fine Chemicals, 
Uppsala, Sweden. Whatman DEAE-cellulose (DE-52) 
was a product of Balston Ltd., UK. Testicular hyal- 
uronidase was obtained from AB Leo, Helsingborg, 
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Sweden, and bacterial chondroitinase ABC from 
Miles Laboratories, Inc., Elkhardt, Ind. 
2.2. Glycosaminoglycans 
35S-labelled chondroitin sulphate and a chondroitin 
sulphate [3sS]hexasaccharide were available in our 
laboratory (Amadb et al., 1974). 
Heparan sulphate isolated from human aorta (HS 
II, ref. [.5,6]) was generously provided by Dr P.-H. 
Iverius of this Institute. 
35S-labelled hepar an sulphate was obtained from 
cultures of human glial cells [7,8] (10 X lo6 cells) 
incubated in the presence of radiosulphate (10 @i 
per ml of Ham’s F-12 [9] at 37°C for 48 h. The 
spent medium (50 ml) was collected and digested 
with crystalline papain for 20 h at 55°C pH 5.5 [lo]. 
The macromolecular 35S-labelled material (1.5 X lo6 
cpm) was recovered by gel chromatography in 1 M 
NaCl on Sephadex G-50 and desalted by passage 
through a column of Sephadex G-50. After lyophili- 
zation, the 35S-labelled galactosaminoglycans were 
eliminated from the preparation by treatment with 
chondroitinase ABC [l I], followed by gel chromato- 
graphy on Sephadex G-50 to remove the degradation 
products, and desalting. The resulting material 
(0.45 X IO6 cpm) was identified as heparan sulphate 
by the following criteria: Treatment with nitrous acid 
(procedure A ref. [IO] ) quantitatively converted the 
polysaccharide to low molecular weight products, 
included in Sephadex G-50. High voltage paper 
electrophoresis of these products showed inorganic 
[35S]sulphate and labelled oligosaccharides corre- 
sponding to an N-[3sS]sulphate to U-[3sS]sulphate 
ratio of 3:2 in the parent polysaccharide. In contrast 
the polysaccharide was resistant to digestion with 
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testicular hyaluronidase or further treatment with 
chondroitinase ABC. Anion exchange chromatography 
on DEAE-cellulose [ 121 revealed a single component 
with the chromatography properties of standard 
monosulphated chondroitin sulphate. 
2.3. Human sera and platelet lysate 
Fresh titrated blood from three healthy donors 
was collected, pooled and centrifuged at 190 g for 
2 X 15 min. The supernatant was divided into three 
parts which were handled individually. All operations 
with intact platelets were performed at room tempe- 
rature; subsequent steps were made at 4°C. 
Platelet-poor serum. The supernatant was recentri- 
fuged at 1250 g for 30 min and the cell-free plasma 
was collected and dialyzed against Eagle’s MEM [ 131. 
The fibrin clot was spun down (5000 g; 20 min) and 
the serum dialysed against 0.15 M NaCl. 
Platelet-rich serum The supernatant was recentri- 
fuged at 1250 g for 30 min. The pellet was suspended 
in l/5 of the plasma supernatant and the resulting 
platelet-rich plasma was converted to serum as 
described above. 
Platelet lysate. The supernatant was further freed 
from red and white blood cells by five centrifugations 
(400 g; 10 min). After the last centrifugation platelets 
were the only cells found in the supernatant on 
examination in the phase contrast microscope. The 
platelets were spun down (1250 g; 30 min), washed in 
phosphate buffered saline (PBS; 3.4 mM KCl, 170 
mM NaCl, 10 mM phosphate, pH 7.3 and recentrifuged 
three times (1250 g; 30 min). The pellet was suspended 
in a small volume of PBS and freeze-thawed five 
times. After dialysis against 0.15 M NaCl a 100 000 g 
supernatant of the lysate was prepared. 
Human sera and platelet lysates were stored at 
-20°C until used. 
2.4. Analytical methods 
Protein was determined by the method of Lowry 
et al. [14]. Uranic acid was determined with the * 
carbazole reaction according to Bitter and Muir [15]. 
Liquid scintillation counting was performed in a 
Packard Model 2002 liquid scintillation counter, using 
Instagel (Packard Instruments) as the scintillation 
medium. 
2.5. Incubations 
35S-labelled polysaccharide ( [3”S] heparan sulphate 
or [35Schondroitin sulphate), 6000 cpm, correspond- 
ing to less than 5 pg of uranic acid) was incubated 
with platelet lysate (0.5 mg of protein) or serum 
(200 ~1) in acetate buffer, pH 5.6,0.075 M NaCl for 
15 h at 37°C in a final volume of 400 J. At the end 
of the incubation period, carrier chondroitin sulphate 
(0.5 mg), sodium chloride (25 mg) and sodium sul- 
phate (1 mg) were added to the incubation mixtures. 
They were then heated to 100°C for 3 min and 
stored at -20°C until analyzed. Deviations from 
standard conditions are indicated in the text. 
2.6. Estimation of polysaccharide breakdown 
The incubation mixtures were centrifuged to 
remove insoluble material and the supernatants 
chromatographed on a column of Sephadex G-100 
(1 X 87 cm) or G-50 (1 X 146 cm), equilibrated with 
1 M NaCl. Elution was made with 1 M NaCl; eluted 
fractions were analyzed for radioactivity by liquid 
scintillation counting or uranic acid by the carbazole 
reaction. The void volume (Ve) and the total volume 
(Vt) of the columns were determined using [3”S] 
chondroitin sulphate and inorganic [“‘S] sulphate, 
respectively. 
3. Results and discussion 
Incubation of [35S] heparan sulphate with platelet 
lysate at pH 5.6 caused a marked depolymerization 
of the substrate. Gel chromatography on Sephadex 
G-100 indicated that the degradation products were 
of oligosaccharide size; inorganic sulphate or sulphated 
monosaccharides were not observed (fig. 1). These 
findings indicate that the polysaccharide was degraded 
by an endoglycosidase, cleaving internal glycosidic 
bonds of the heparan sulphate chains. The observed 
degradation was not due to exoenzymes to any 
major extent since no low-molecular weight products 
(e.g. inorganic sulphate) were detectable. The size of 
the degradation products was further analyzed by 
chromatography on Sephadex G-50. A major portion 
of the material (75%) was eluted from the column 
with a K, value [ 161 of 0.18-0.70. The most 
retarded components had an apparent size similar to 
that of a standard chondroitin sulphate hexasaccharide 
(Km, 0.69). 
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Fig.1. Gel chromatography on Sephadcx G-100 of 
[35S]heparan sulphate, incubated with platelet lysate. 
(-) Nontreated enzyme; (w ) heat-inactivated 
enzyme. V, and Vt of the column are indicated by arrows. 
The gel chromatography pattern was essentially 
the same after reincubation with fresh enzyme. Thus, 
some of the glycosidic bonds in the substrate polymer 
were apparently resistant to the endoglycosidase. The 
presence of resistant fragments of different size may 
be ascribed to a structural heterogeneity in the heparan 
sulphate preparation [ 171. 
Degradation of a standard preparation of non- 
labelled heparan sulphate (HS II) was also effected by 
the platelet endoglycosidase. Thus, after incubation 
of 2 mg of HS II with 4 mg of platelet protein, 
carbazole-positive depolymerization products were 
demonstrable by gel chromatography on Sephadex 
G-100. No monosaccharides were detected, in con- 
firmation of the view that the degradation of heparan 
sulphate was achieved by an endoglycosidase rather 
than by exoglycosidases. 
The platelet heparitinase* showed maximal activity, 
* Pending adequate nomenclature, the term hcparitinase is 
used in analogy with the bacterial enzyme described by 
Linker [ 181. 
in acetate or phosphate buffers, at pH 5.0 to 5.6, as 
shown by gel chromatography of incubation products. 
No degradative activity, i.e. neither endo- nor 
exoglycosidases, could be demonstrated at pH 3.6 
(acetate buffer). In contrast, appreciable endo- 
glycosidase activity was retained at neutral pH 
(phosphate buffer). [35S]chondroitin sulphate was 
resistant to degradation with the platelet enzyme 
preparation under standard incubation conditions. 
These findings clearly distinguish the enzyme from 
the group of hyaluronidase-like enzymes [ 19,201, 
demonstrated in other tissues. 
Incubation of [35S]lleparan sulphate with human 
serum derived from platelet-poor plasma had no 
appreciable effect on the size of the [3”S] heparan 
sulphate chains (fig.2). In contrast, serum derived 
from platelet-rich plasma showed heparan sulphate- 
depolymerizing activity, causing a moderate shift in 
the size distribution of the polysaccharide molecules 
(fig.2). This finding suggests that the presence of 
heparitinase in the platelet lysate was not due to 
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Fig.2. Gel chromatography on Sephadex GIOO of [ 35S] 
heparan sulphate, incubated with human serum derived from 
platelet-rich (- ) or platelet-poor (M ) plasma. V. 
and Vt of the column are indicated by arrows. 
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contaminating serum proteins; rather the enzyme 
activity derived from the platelets. 
Heparan sulphate degrading endoglycosidases from 
mammalian tissues have long remained unrecognized. 
Only recently the presence of such an enzyme activity 
in rat liver lysosomes was reported from this laboratory 
[21]. The rat liver heparitinase had a similar effect on 
the substrate, yielding oligosaccharides as end products, 
and had a similar pH-dependence, showing an opti- 
mum near pH 5.6. Further experiments will show 
whether the two enzymes have additional properties 
in common or if they are, in fact, identical. 
The occurrence in platelets of a heparitinase 
suggests a previously unknown platelet function. 
Heparan sulphate does not appear to be a constituent 
of platelets [22] and therefore, the heparitinase is 
probably not involved in catabolic processes within 
the platelets proper. Rather, the natural substrates 
for the platelet heparitinase should be found in 
association with other cells within or near the vascular 
space. Heparan sulphate has been identified in a 
number of mammalian cells, including rabbit endo- 
thelial cells [23], and bovine arterial cells [24] . 
Heparan sulphate is largely associated with the plasma 
membrane; in fact the localization of heparan 
sulphate to the external surface of endothelial cells 
has been demonstrated by its availability to degrada- 
tion with a bacterial glycosidase [25]. Preliminary 
experiments indicate that heparan sulphate may be 
released from cultured glial cells by treatment with 
platelet lysate, the digestion products appearing as 
oligosaccharides in the medium. In vivo the platelet 
enzyme may exert a similar effect on the heparan 
sulphate of endothelial cells. The removal of mem- 
brane associated heparan sulphate from these cells 
may significantly modify the external surface and 
thus influence the interaction between the endothelial 
cells and circulating components. 
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